Mallinckrodt Hospital Products, Inc.

( )
CADX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -2.92%158.010.7%$1349.36m
PFEPfizer Inc. -0.89%33.520.9%$1231.01m
BMYBristol-Myers Squibb Co. -1.35%61.261.0%$864.73m
MRKMerck & Co., Inc. -2.73%72.580.7%$812.99m
ABBVAbbVie, Inc. 0.28%107.631.9%$810.79m
LLYEli Lilly & Co. 0.43%204.691.1%$785.50m
AZNAstraZeneca Plc -1.08%48.381.2%$514.48m
GSKGlaxoSmithKline Plc -2.24%33.610.2%$264.35m
NVSNovartis AG -0.87%85.960.2%$189.07m
SNYSanofi 0.20%45.890.2%$168.76m
VTRSViatris, Inc. -1.33%14.850.0%$142.39m
VERUVeru, Inc. -3.22%13.820.0%$115.13m
CVACCureVac NV 1.43%94.300.0%$107.78m
VYNEVYNE Therapeutics, Inc. -5.45%7.460.0%$94.74m
NVONovo Nordisk A/S -1.47%71.280.1%$91.66m

Company Profile

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.